Does the media prefer NRIX or ALLO?

In the previous week, Nurix Therapeutics had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 2 mentions for Nurix Therapeutics and 1 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.01 beat Nurix Therapeutics' score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, ALLO or CDNA?

CareDx has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allogene Therapeutics $20K 29,193.91 -$190.89M -$0.67 N/A CareDx $379.80M 7.33 -$21.35M $2.07 26.00

Does the media refer more to ALLO or CDNA?

In the previous week, CareDx had 3 more articles in the media than Allogene Therapeutics. MarketBeat recorded 4 mentions for CareDx and 1 mentions for Allogene Therapeutics. CareDx's average media sentiment score of 0.88 beat Allogene Therapeutics' score of 0.01 indicating that CareDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CareDx 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VRDN or ALLO?

In the previous week, Viridian Therapeutics had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 2 mentions for Viridian Therapeutics and 1 mentions for Allogene Therapeutics. Viridian Therapeutics' average media sentiment score of 1.77 beat Allogene Therapeutics' score of 0.01 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is VERA or ALLO more profitable?

Allogene Therapeutics' return on equity of -50.04% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vera Therapeutics N/A -84.13% -66.79% Allogene Therapeutics N/A -50.04% -36.74%

Does the media refer more to VERA or ALLO?

In the previous week, Vera Therapeutics had 26 more articles in the media than Allogene Therapeutics. MarketBeat recorded 27 mentions for Vera Therapeutics and 1 mentions for Allogene Therapeutics. Vera Therapeutics' average media sentiment score of 0.65 beat Allogene Therapeutics' score of 0.01 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 10 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BCRX or ALLO?

In the previous week, BioCryst Pharmaceuticals had 6 more articles in the media than Allogene Therapeutics. MarketBeat recorded 7 mentions for BioCryst Pharmaceuticals and 1 mentions for Allogene Therapeutics. BioCryst Pharmaceuticals' average media sentiment score of 0.71 beat Allogene Therapeutics' score of 0.01 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Allogene Therapeutics (ALLO) Competitors

$1.69 -0.04 (-2.31%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.68 0.00 (-0.30%)

As of 09/18/2026 07:30 PM Eastern

Compare

ALLO vs. NRIX, CDNA, VRDN, VERA, and BCRX

Should you buy Allogene Therapeutics stock or one of its competitors? Allogene Therapeutics's main competitors and comparable companies include Nurix Therapeutics (NRIX), CareDx (CDNA), Viridian Therapeutics (VRDN), Vera Therapeutics (VERA), and BioCryst Pharmaceuticals (BCRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Allogene Therapeutics compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Nurix Therapeutics currently has a consensus price target of $34.21, indicating a potential upside of 34.49%. Allogene Therapeutics has a consensus price target of $8.30, indicating a potential upside of 391.12%. Given Allogene Therapeutics' higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

83.6% of Allogene Therapeutics shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nurix Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

In the previous week, Nurix Therapeutics had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 2 mentions for Nurix Therapeutics and 1 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.01 beat Nurix Therapeutics' score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Allogene Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Allogene Therapeutics' return on equity of -50.04% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Allogene Therapeutics	N/A	-50.04%	-36.74%

Allogene Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	31.44	-$264.46M	-$3.45	N/A
Allogene Therapeutics	$20K	29,193.91	-$190.89M	-$0.67	N/A

Summary

Allogene Therapeutics beats Nurix Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Allogene Therapeutics compare to CareDx?

Allogene Therapeutics (NASDAQ:ALLO) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Allogene Therapeutics presently has a consensus target price of $8.30, suggesting a potential upside of 391.12%. CareDx has a consensus target price of $51.20, suggesting a potential downside of 4.89%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Allogene Therapeutics is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63

CareDx has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	29,193.91	-$190.89M	-$0.67	N/A
CareDx	$379.80M	7.33	-$21.35M	$2.07	26.00

In the previous week, CareDx had 3 more articles in the media than Allogene Therapeutics. MarketBeat recorded 4 mentions for CareDx and 1 mentions for Allogene Therapeutics. CareDx's average media sentiment score of 0.88 beat Allogene Therapeutics' score of 0.01 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CareDx	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.6% of Allogene Therapeutics shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 2.4% of CareDx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Allogene Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, CareDx has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market.

CareDx has a net margin of 24.23% compared to Allogene Therapeutics' net margin of 0.00%. CareDx's return on equity of 2.87% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-50.04%	-36.74%
CareDx	24.23%	2.87%	2.17%

Summary

CareDx beats Allogene Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Allogene Therapeutics compare to Viridian Therapeutics?

Viridian Therapeutics (NASDAQ:VRDN) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Allogene Therapeutics has lower revenue, but higher earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	35.18	-$342.60M	-$3.37	N/A
Allogene Therapeutics	$20K	29,193.91	-$190.89M	-$0.67	N/A

Viridian Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

Allogene Therapeutics has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -505.86%. Allogene Therapeutics' return on equity of -50.04% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
Allogene Therapeutics	N/A	-50.04%	-36.74%

83.6% of Allogene Therapeutics shares are owned by institutional investors. 2.4% of Viridian Therapeutics shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Viridian Therapeutics had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 2 mentions for Viridian Therapeutics and 1 mentions for Allogene Therapeutics. Viridian Therapeutics' average media sentiment score of 1.77 beat Allogene Therapeutics' score of 0.01 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viridian Therapeutics currently has a consensus price target of $38.54, suggesting a potential upside of 75.17%. Allogene Therapeutics has a consensus price target of $8.30, suggesting a potential upside of 391.12%. Given Allogene Therapeutics' higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Viridian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Summary

Allogene Therapeutics beats Viridian Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Allogene Therapeutics compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Allogene Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A
Allogene Therapeutics	$20K	29,193.91	-$190.89M	-$0.67	N/A

Vera Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

Vera Therapeutics presently has a consensus price target of $80.15, indicating a potential upside of 135.75%. Allogene Therapeutics has a consensus price target of $8.30, indicating a potential upside of 391.12%. Given Allogene Therapeutics' higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

In the previous week, Vera Therapeutics had 26 more articles in the media than Allogene Therapeutics. MarketBeat recorded 27 mentions for Vera Therapeutics and 1 mentions for Allogene Therapeutics. Vera Therapeutics' average media sentiment score of 0.65 beat Allogene Therapeutics' score of 0.01 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	10 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Allogene Therapeutics' return on equity of -50.04% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-84.13%	-66.79%
Allogene Therapeutics	N/A	-50.04%	-36.74%

Summary

Vera Therapeutics and Allogene Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Allogene Therapeutics compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

In the previous week, BioCryst Pharmaceuticals had 6 more articles in the media than Allogene Therapeutics. MarketBeat recorded 7 mentions for BioCryst Pharmaceuticals and 1 mentions for Allogene Therapeutics. BioCryst Pharmaceuticals' average media sentiment score of 0.71 beat Allogene Therapeutics' score of 0.01 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCryst Pharmaceuticals has higher revenue and earnings than Allogene Therapeutics. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$940.61M	2.36	$263.86M	-$1.50	N/A
Allogene Therapeutics	$20K	29,193.91	-$190.89M	-$0.67	N/A

BioCryst Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Allogene Therapeutics has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. Allogene Therapeutics' return on equity of -50.04% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Allogene Therapeutics	N/A	-50.04%	-36.74%

BioCryst Pharmaceuticals currently has a consensus target price of $20.40, suggesting a potential upside of 135.02%. Allogene Therapeutics has a consensus target price of $8.30, suggesting a potential upside of 391.12%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Summary

Allogene Therapeutics beats BioCryst Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Allogene Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALLO vs. The Competition

Export

Metric	Allogene Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$597.70M	$3.91B	$7.25B	$13.13B
Dividend Yield	N/A	3.65%	2.57%	12.94%
P/E Ratio	-2.52	14.08	273.81	25.39
Price / Sales	29,193.91	1,407.75	692.78	109.00
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	1.30	15.45	10.45	6.33
Net Income	-$190.89M	-$22.78M	$3.48B	$358.24M
7 Day Performance	-5.06%	-1.22%	0.88%	1.17%
1 Month Performance	-24.22%	-4.44%	-1.59%	-2.59%
1 Year Performance	45.69%	37.78%	18.08%	5.97%

Allogene Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALLO Allogene Therapeutics	1.7487 of 5 stars	$1.69 -2.3%	$8.30 +391.1%	+39.7%	$597.70M	$20K	N/A	152	High Trading Volume
NRIX Nurix Therapeutics	2.115 of 5 stars	$26.14 flat	$34.21 +30.9%	+183.6%	$2.71B	$83.98M	N/A	300	Positive News
CDNA CareDx	2.6104 of 5 stars	$50.88 flat	$51.20 +0.6%	+264.5%	$2.63B	$379.80M	24.58	740
VRDN Viridian Therapeutics	3.0494 of 5 stars	$22.92 flat	$38.54 +68.1%	+12.1%	$2.60B	$70.85M	N/A	50	Positive News
VERA Vera Therapeutics	2.8299 of 5 stars	$35.89 flat	$81.15 +126.1%	+29.1%	$2.59B	N/A	N/A	40	Analyst Forecast Insider Trade Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALLO) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allogene Therapeutics (ALLO) Competitors

ALLO vs. NRIX, CDNA, VRDN, VERA, and BCRX

How does Allogene Therapeutics compare to Nurix Therapeutics?

Summary

How does Allogene Therapeutics compare to CareDx?

Summary

How does Allogene Therapeutics compare to Viridian Therapeutics?

Summary

How does Allogene Therapeutics compare to Vera Therapeutics?

Summary

How does Allogene Therapeutics compare to BioCryst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLO vs. The Competition

Allogene Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allogene Therapeutics (ALLO) Competitors

ALLO vs. NRIX, CDNA, VRDN, VERA, and BCRX

How does Allogene Therapeutics compare to Nurix Therapeutics?

Do analysts recommend NRIX or ALLO?

Do institutionals & insiders believe in NRIX or ALLO?

Which has more risk and volatility, NRIX or ALLO?

Does the media prefer NRIX or ALLO?

Is NRIX or ALLO more profitable?

Which has higher earnings & valuation, NRIX or ALLO?

Summary

How does Allogene Therapeutics compare to CareDx?

Do analysts rate ALLO or CDNA?

Which has better earnings & valuation, ALLO or CDNA?

Does the media refer more to ALLO or CDNA?

Do insiders and institutionals hold more shares of ALLO or CDNA?

Which has more risk & volatility, ALLO or CDNA?

Is ALLO or CDNA more profitable?

Summary

How does Allogene Therapeutics compare to Viridian Therapeutics?

Which has stronger earnings & valuation, VRDN or ALLO?

Which has more volatility and risk, VRDN or ALLO?

Is VRDN or ALLO more profitable?

Do institutionals & insiders have more ownership in VRDN or ALLO?

Does the media prefer VRDN or ALLO?

Do analysts recommend VRDN or ALLO?

Summary

How does Allogene Therapeutics compare to Vera Therapeutics?

Which has preferable earnings & valuation, VERA or ALLO?

Which has more volatility & risk, VERA or ALLO?

Do analysts recommend VERA or ALLO?

Does the media refer more to VERA or ALLO?

Do institutionals and insiders believe in VERA or ALLO?

Is VERA or ALLO more profitable?

Summary

How does Allogene Therapeutics compare to BioCryst Pharmaceuticals?

Does the media refer more to BCRX or ALLO?

Which has better earnings & valuation, BCRX or ALLO?

Which has more volatility and risk, BCRX or ALLO?

Do institutionals & insiders have more ownership in BCRX or ALLO?

Is BCRX or ALLO more profitable?

Do analysts recommend BCRX or ALLO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLO vs. The Competition

Allogene Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools